📊 CYRX Key Takeaways
Is Cryoport, Inc. (CYRX) a Good Investment?
Cryoport exhibits a paradoxical financial profile with strong profitability metrics (44.4% net margin, 15.6% ROE) but severe operational weakness (-20.9% operating margin, -$25M free cash flow). The 11.4% net income growth is driven by non-operating gains rather than core business improvement, and negative operating cash flow signals fundamental business sustainability concerns despite reported profitability.
Cryoport’s balance sheet is solid, with substantial cash, good liquidity, and modest leverage, but the core business remains fundamentally weak. Revenue is flat, operating margins are deeply negative, and both operating cash flow and free cash flow are negative, which suggests the strong net income and EPS likely do not reflect durable operating performance.
Why Buy Cryoport, Inc. Stock? CYRX Key Strengths
- Strong net profit margin of 44.4% demonstrates pricing power and efficient cost management at bottom line
- Healthy balance sheet with $250.5M cash, 2.17x current ratio, and conservative 0.23x debt/equity ratio providing financial flexibility
- Solid gross margin of 47.1% indicates competitive products and strong demand in pharmaceutical logistics segment
- Strong liquidity with $250.49M in cash and current ratio of 2.17x
- Low balance-sheet leverage with debt/equity of 0.23x
- Healthy gross margin of 47.1%, indicating the underlying service mix still has economic potential
CYRX Stock Risks: Cryoport, Inc. Investment Risks
- Severe operating loss of $36.8M with -20.9% operating margin indicates core business is unprofitable despite net income gains
- Negative free cash flow of -$25M with -$8.6M operating cash flow raises red flags about earnings quality and sustainability
- Disconnect between reported net income growth and operational deterioration suggests one-time gains or accounting adjustments masking business decline
- Negative interest coverage ratio of -27.5x indicates inability to service debt from operations
- Operating losses remain significant with a -20.9% operating margin
- Cash generation is weak, with negative operating cash flow and -$25.02M free cash flow
- Revenue growth is stalled, raising concerns about the quality and sustainability of earnings
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Operating income trajectory and operating margin expansion/contraction
- Revenue growth sustainability and gross margin stability
- Quality of earnings analysis to isolate operating vs non-operating income components
- Operating margin and operating cash flow
- Revenue growth and free cash flow trend
Cryoport, Inc. (CYRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.17x current ratio provides a solid financial cushion.
CYRX Profit Margin, ROE & Profitability Analysis
CYRX vs Healthcare Sector: How Cryoport, Inc. Compares
How Cryoport, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cryoport, Inc. Stock Overvalued? CYRX Valuation Analysis 2026
Based on fundamental analysis, Cryoport, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cryoport, Inc. Balance Sheet: CYRX Debt, Cash & Liquidity
CYRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cryoport, Inc.'s revenue has declined by 26% over the 5-year period, indicating business contraction. The most recent EPS of $-2.21 indicates the company is currently unprofitable.
CYRX Revenue Growth, EPS Growth & YoY Performance
CYRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $38.3M | $805.0K | $-0.02 |
| Q2 2025 | $39.7M | -$78.0M | $-1.62 |
| Q1 2025 | $37.3M | -$12.0M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cryoport, Inc. Dividends, Buybacks & Capital Allocation
CYRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cryoport, Inc. (CIK: 0001124524)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYRX
What is the AI rating for CYRX?
Cryoport, Inc. (CYRX) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYRX's key strengths?
Claude: Strong net profit margin of 44.4% demonstrates pricing power and efficient cost management at bottom line. Healthy balance sheet with $250.5M cash, 2.17x current ratio, and conservative 0.23x debt/equity ratio providing financial flexibility. ChatGPT: Strong liquidity with $250.49M in cash and current ratio of 2.17x. Low balance-sheet leverage with debt/equity of 0.23x.
What are the risks of investing in CYRX?
Claude: Severe operating loss of $36.8M with -20.9% operating margin indicates core business is unprofitable despite net income gains. Negative free cash flow of -$25M with -$8.6M operating cash flow raises red flags about earnings quality and sustainability. ChatGPT: Operating losses remain significant with a -20.9% operating margin. Cash generation is weak, with negative operating cash flow and -$25.02M free cash flow.
What is CYRX's revenue and growth?
Cryoport, Inc. reported revenue of $176.2M.
Does CYRX pay dividends?
Cryoport, Inc. does not currently pay dividends.
Where can I find CYRX SEC filings?
Official SEC filings for Cryoport, Inc. (CIK: 0001124524) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYRX's EPS?
Cryoport, Inc. has a diluted EPS of $1.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cryoport, Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYRX stock overvalued or undervalued?
Valuation metrics for CYRX: ROE of 15.6% (sector avg: 15%), net margin of 44.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy CYRX stock in 2026?
Our dual AI analysis gives Cryoport, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CYRX's free cash flow?
Cryoport, Inc.'s operating cash flow is $-8.6M, with capital expenditures of $16.4M. FCF margin is -14.2%.
How does CYRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 44.4% (avg: 12%), ROE 15.6% (avg: 15%), current ratio 2.17 (avg: 2).